Recruiting

taRgeting bEtA-Cell Function To achIeVe Remission of Type 2 diAbeTEs

The main objective of the REACTIVATE study is to investigate whether a period of intensive insulin therapy using closed-loop technology, when combined with diet and lifestyle education, can restore beta-cell function and achieve remission of recent-onset type 2 diabetes. This is a single-centre, open-label, randomised, parallel design study comparing up to 12 weeks of fully closed-loop insulin delivery to standard care with a glucose sensor in adults with recent-onset type 2 diabetes. The primary outcome is the…

I'm interested View official listing
ClinicalTrials.gov IDNCT06844539
PhaseNA
Enrollment56
SponsorUniversity of Cambridge
Age18 Years and older
SexALL
I'm interested View official listing

Conditions studied

Type 2 Diabetes

About this study

The main objective of the REACTIVATE study is to investigate whether a period of intensive insulin therapy using closed-loop technology, when combined with diet and lifestyle education, can restore beta-cell function and achieve remission of recent-onset type 2 diabetes. This is a single-centre, open-label, randomised, parallel design study comparing up to 12 weeks of fully closed-loop insulin delivery to standard care with a glucose sensor in adults with recent-onset type 2 diabetes. The primary outcome is the number of participants achieving remission of diabetes at 52 weeks, defined as HbA1c below 48mmol/mol after 12 or more weeks off all diabetes medications. Other key outcomes include area under the curve for C-peptide and glucose during mixed meal tolerance test, the proportion of time spent with glucose levels within and above the target glucose range and mean sensor glucose as recorded by glucose sensor at 52 weeks. Safety evaluation comprises severe hypoglycaemic episodes, and other adverse and serious adverse events. Utility and human factors outcomes include glucose sensor and closed-loop usage, questionnaires and semi-structured interviews.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Aged 18 years and older * Type 2 diabetes diagnosed \>6 months and ≤5 years ago * Treatment with glucose lowering medication for at least 3 months * HbA1c \>48 mmol/mol on analysis from local laboratory or equivalent * Willing to wear study devices and follow study instructions * Capacity to consent to participate in the study Exclusion Criteria: * Type 1 diabetes * Current use of insulin pump * Current use of any closed-loop system * Any physical/psychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by study clinician * Known or suspected allergy against insulin * Pregnancy, planned pregnancy, or breast feeding * Severe visual or hearing impairment * Medically documented allergy towards the adhesive of plasters * Serious skin diseases located at places of the body potentially used for localisation of the glucose sensor * Drug or alcohol misuse * Group 2 driving licence holder

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-19.